-
Maternal cardiac function in women at high risk for pre-eclampsia treated with 150 mg aspirin or placebo: an observational study.
Ling HZ, Jara PG, Bisquera A, Poon LC, Nicolaides KH, Kametas NA.
BJOG 2020;127:1018-1025. pdf -
Maternal cardiac function at 19-23 weeks' gestation in the prediction of pre-eclampsia.
Gibbone E, Wright A, Vallenas Campos R, Sanchez Sierra A, Nicolaides KH, Charakida M.
Ultrasound Obstet Gynecol 2021;57:739-747 pdf -
Maternal Cardiac Assessment at 35 to 37 Weeks Improves Prediction of Development of Preeclampsia.
Garcia-Gonzalez C, Georgiopoulos G, Azim SA, Macaya F, Kametas N, Nihoyannopoulos P, Nicolaides KH, Charakida M.
Hypertension 2020;76:514-522. pdf -
Fetal cardiac function at 35-37 weeks' gestation in pregnancies that subsequently develop pre-eclampsia.
Semmler J, Garcia-Gonzalez C, Sanchez Sierra A, Gallardo Arozena M, Nicolaides KH, Charakida M.
Ultrasound Obstet Gynecol 2021;57:417:422 pdf -
Chronic hypertension and adverse pregnancy outcomes: a cohort study.
Panaitescu AM, Syngelaki A, Prodan N, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:228-235. pdf -
Effect of change in posture on maternal functional hemodynamics at 35-37 weeks' gestation.
Guy GP, Ling HZ, Machuca M, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2018;51:368-374. pdf -
Maternal cardiac function at 35-37 weeks' gestation: prediction of pre-eclampsia and gestational hypertension.
Guy GP, Ling HZ, Garcia P, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:61-66. pdf -
Maternal cardiovascular function at 35-37 weeks' gestation: Relation to maternal characteristics.
Guy GP, Ling HZ, Garcia P, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:39-45. pdf -
Inverted Pyramid of Care.
Sonek JD, Kagan KO, Nicolaides KH.
Clin Lab Med 2016;36:305-17. pdf -
Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation.
Bujold E, Roberge S, Nicolaides KH.
Prenat Diagn 2014;34:642-8. pdf -
Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes.
Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013;33:215-23. pdf -
Maternal age and adverse pregnancy outcomes: a cohort study.
Khalil A, Syngelaki A, Maiz N, Zinevich Y, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;42:634-43. pdf -
Maternal racial origin and adverse pregnancy outcome: a cohort study.
Khalil A, Rezende J, Akolekar R, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:278-85. -
Quantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, down's syndrome, preterm delivery and preeclampsia.
Chambers AE, Griffin C, Naif SA, Mills I, Mills WE, Syngelaki A, Nicolaides KH, Banerjee S.
Reprod Biol Endocrinol 2012;10:113. -
Body Mass Index at 11-13 Weeks' Gestation and Pregnancy Complications.
Syngelaki A, Bredaki FE, Vaikousi E, Maiz N, Nicolaides KH.
Fetal Diagn Ther 2011;30:250-65. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Association of placental volume measured by MRI and birth weight percentile.
Derwig IE, Akolekar R, Zelaya FO, Gowland PA, Barker GJ, Nicolaides KH.
J Magn Reson Imaging 2011;34:1125-30. -
First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Poon LC, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH.
Prenat Diagn 2009;29:553-9. -
First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome.
Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH.
Obstet Gynecol 2008;112:1082-90.